FINWIRES · TerminalLIVE
FINWIRES

Cencora Pick of the Week at Smart Insider Following Chairman's Share Purchase

By

Cencora (COR) was Smart Insider's stock pick of the week after Chair Mark Durcan bought $1 million in company shares on May 28.

Durcan, who has served as chair since October 2025 and has been a director since 2015, acquired 4,000 shares at $266 apiece, Smart Insider said in a Tuesday note.

The purchase followed a decline in the stock after the company's Q2 earnings report, according to Smart Insider.

Cencora also announced plans to resume share repurchases, authorizing up to $2 billion after pausing the program in January, according to the note.

The transaction was Durcan's fourth purchase during his time on the board, with previous acquisitions ranging from about $100,000 to $200,000.

Smart Insider described the purchase as "unusually large" for Durcan, adding that he did not buy shares while serving on the boards of other companies, including ASML (ASML) and Advanced Micro Devices (AMD), or during his tenure as chief executive of Micron Technology (MU).

Smart Insider ranked Cencora +1, indicating a strong positive signal.

Price: $280.57, Change: $-1.06, Percent Change: -0.38%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC